Dyskinesia hampers the quality of life for most Parkinson's disease patients following several years of therapy. However, the severity of L-Dopa-induced dyskinesia (LID) varies between patients ...

shallow and rapid breathing ("respiratory dyskinesia"), pelvic thrusting ("copulatory dyskinesia"), crossing and uncrossing of legs, shifting of body weight from one to the other leg, pacing or ...

Previous studies in a rat model of Parkinson disease (PD) have shown that dyskinesia induced by L-DOPA—a treatment-limiting adverse effect of long-term administration—is caused by the release ...

Over the years, the brain of a Parkinson's patient adapts to the levodopa treatment, which is why levodopa causes dyskinesia in the long term, said Abhilasha Vishwanath, the study's lead author ...

In early, levodopa-naive PD patients, Stalevo induced more dyskinesia than similar dosages of levodopa/carbidopa, so the regimen tested (target maintenance dose Stalevo 100 four-times daily given ...

University of Arizona researchers have advanced understanding of a common complication in Parkinson’s disease treatment: involuntary movements known as levodopa-induced dyskinesia. Published in Brain, ...

Onapgo is the first subcutaneous apomorphine infusion device approved to treat motor fluctuations in Parkinson’s disease ... on” time without troublesome dyskinesia, the mean change from ...

Opens in a new tab or window The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus ...

Bayer’s Parkinson’s disease cell therapy is moving into late ... a medication is working for patients without troublesome dyskinesia, or involuntary movements that cause significant disability.